Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
iShares Genomics Immunology and Healthcare ETF (IDNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: IDNA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit -3.04% | Avg. Invested days 46 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | ETF Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Volume (30-day avg) - | Beta 1.08 | 52 Weeks Range 17.14 - 25.49 | Updated Date 06/30/2025 |
52 Weeks Range 17.14 - 25.49 | Updated Date 06/30/2025 |
Upturn AI SWOT
iShares Genomics Immunology and Healthcare ETF
ETF Overview
Overview
The iShares Genomics Immunology and Healthcare ETF (IDNA) seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from advancements in genomics, immunology, and bioengineering.
Reputation and Reliability
BlackRock is one of the world's largest asset managers with a strong reputation and long track record.
Management Expertise
BlackRock has extensive expertise in managing ETFs across various asset classes and investment strategies.
Investment Objective
Goal
To track the investment results of an index composed of developed and emerging market companies that could benefit from advancements in genomics, immunology, and bioengineering.
Investment Approach and Strategy
Strategy: The ETF aims to track the ICE FactSet Genomics and Immuno Biopharma Index.
Composition The ETF primarily holds stocks in the healthcare and biotechnology sectors. It focuses on companies involved in genomics, immunology, and healthcare innovation.
Market Position
Market Share: IDNA's market share in the genomics and immunology ETF sector is moderate.
Total Net Assets (AUM): 253785280
Competitors
Key Competitors
- ARKG
- GNOM
- BTEC
Competitive Landscape
The genomics and immunology ETF industry is competitive. IDNA benefits from BlackRock's brand and broad reach, but faces competition from more focused and actively managed ETFs like ARKG, which may offer higher growth potential but also greater risk.
Financial Performance
Historical Performance: Historical performance data is not directly included here but can be obtained from financial data providers.
Benchmark Comparison: Benchmark comparison data is not directly included here but can be obtained from financial data providers by comparing IDNA's returns to the ICE FactSet Genomics and Immuno Biopharma Index.
Expense Ratio: 0.47
Liquidity
Average Trading Volume
IDNA's average trading volume is moderate, indicating reasonable liquidity for most investors.
Bid-Ask Spread
The bid-ask spread is typically tight, reflecting the ETF's reasonable liquidity.
Market Dynamics
Market Environment Factors
Economic indicators, sector growth prospects (biotechnology and healthcare), and current market conditions affecting the overall healthcare and technology sectors influence IDNA's performance.
Growth Trajectory
The growth trajectory of IDNA depends on advancements and adoption in genomics, immunology, and healthcare innovation. Changes to strategy and holdings are disclosed periodically by BlackRock.
Moat and Competitive Advantages
Competitive Edge
IDNA benefits from BlackRock's established ETF platform, offering a cost-effective and diversified exposure to companies benefiting from advancements in genomics, immunology, and bioengineering. Its passive approach allows investors to gain broad exposure at a lower expense ratio than actively managed funds. This diversified approach may appeal to investors seeking broad exposure to these sectors, without relying on specific stock picking within the genomics and immunology space.
Risk Analysis
Volatility
IDNA's historical volatility is moderate to high, reflecting the inherent volatility of the biotechnology and healthcare sectors.
Market Risk
Market risk includes sector-specific risks such as regulatory changes in healthcare, patent expirations, clinical trial failures, and broader economic downturns affecting investment in innovative technologies.
Investor Profile
Ideal Investor Profile
The ideal investor profile includes those seeking exposure to the genomics, immunology, and healthcare innovation sectors, with a moderate to high risk tolerance.
Market Risk
IDNA is best suited for long-term investors seeking thematic exposure to disruptive technologies in healthcare.
Summary
The iShares Genomics Immunology and Healthcare ETF (IDNA) provides diversified exposure to companies benefiting from advancements in genomics, immunology, and healthcare innovation. Managed by BlackRock, it tracks the ICE FactSet Genomics and Immuno Biopharma Index, offering a cost-effective way to access this rapidly evolving sector. However, investors should be aware of the sector's inherent volatility and potential regulatory risks. IDNA may be suitable for long-term investors with a moderate to high risk tolerance seeking thematic exposure in their portfolios.
Similar ETFs
Sources and Disclaimers
Data Sources:
- iShares website
- ETF.com
- Bloomberg
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About iShares Genomics Immunology and Healthcare ETF
Exchange NYSE ARCA | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.